Abstract
Background and hypothesis Salience is a critical mechanism for animal survival. Aberrant salience is essentially implicated in psychosis, involving the midbrain–striatum–hippocampus and the anterior cingulate cortex (ACC)–insula salience network (SN) systems. However, whether these two systems jointly or independently contribute to psychosis traits, staging, and state remains unknown.
Study design Eight scanners at seven institutions recruited 209 subjects with psychosis at the ultra-high-risk (UHR), first-episode (FEP), and chronic (ChrP) stages and 279 matched healthy controls (HC). Resting-state functional MRI data, which were intensively denoised and scanner effect-removed, revealed the two systems comprising five networks: midbrain-thalamic and striatal parts of the basal ganglia network (BGN-MbThal and BGN-Str), the medial temporal lobe network (MTLN), and the ACC and insular parts of the SN (SN-ACC and SN-Ins). Group differences, correlations with positive symptoms, and effects of medication/psychosis type of the networks were investigated in each psychosis stage.
Study results Connectivity within the SN-ACC was reduced in UHR compared to HC (p<0.05, family-wise-error [FWE] corrected) and in the FEP and ChrP stages at liberal thresholds, with effect sizes of UHR>FEP>ChrP. FEP showed reduced connectivity within the BGN-MbThal, increased brain-state instability among the five networks, and positive correlations between positive symptoms and connectivity within and between the MTLN (all p<0.05, FWE). The correlation was stronger in unmedicated than in medicated, and in affective than in non-affective psychosis patients (p<0.05, FWE).
Conclusions The results provide a novel concept that the two salience mechanisms work in an integrated and separate manner in psychosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by JSPS/MEXT KAKENHI grants 26461767 (JM), 17H04248 (JM), 18H05130 (JM), 20H05064 (JM), 19H03583 (HT), 23120009 (HT), 16H06572 (HT), 20K21567 (HT), 15H04893 (TM), 16H06397 (TM), JP16H06280 (KK), JP18K07550 (TT), and JP21K12153 (KN); JST ImPACT grant 15808865 (TM) and Moonshot R&D grant JPMJMS2021 (SK and KK); grants from the Japan Foundation for Aging and Health (HT); AMED Strategic Research Program for Brain Sciences grants 17dm0107044h0005 (HT) and 20dm0107088h0005 (TM), Brain/MINDS & beyond studies 21dm0307008h0004 (JM, HT), 20dm0307102h0002 (TM), JP21dm0307001 (KK), JP21dm020769 (KK), JP21dm0307004 (SK and KK), and JP21dm0307002 (RH), Brain Mapping by Integrated Neurotechnologies for Disease Studies JP20dm0207069 (SK and KK), and grants JP21dk0307103 (RH) and JP21uk1024002 (RH); Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders of NCNP (RH); Novartis Pharma Research Grant (JM); a grant from SENSHIN Medical Research Foundation (JM, HT); a grant from SUZUKEN Memorial Foundation (JM); Tanabe-Mitsubishi Pharma Research Grant (JM); a grant from Uehara memorial foundation; Kyoto University Global Frontier Project for Young Professionals (JM); Takeda Science Foundation (JM and HT); Kobayashi Magobei Memorial Foundation (HT); Smoking Research Foundation (HT); the Kato Memorial Trust for Nambyo Research (TM); the National Institute of Mental Health (NIMH) grant numbers MH-094268 (AS), MH-092443 (AS), MH-105660 (AS), and the Silvio O. Conte Center funded by NIMH (AS); the National Institute of Health grant numbers P41EB015909 (SM) and R01NS084957 (SM); grants from Stanley (AS), S-R/RUSK (AS) and NARSAD (AS). Some of the participant recruitment supported by Tanabe Mitsubishi Pharm. Co. Ltd. (AS), and a Wellcome Trust fellowship grant WT087779MA (TWB).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
After receiving a complete description of the study, all participants provided written informed consent. The study design was approved by the institutional review boards of all sites: approved by Hammersmith Hospital Research Ethics Committee (IoPPN); approved by Johns Hopkins Medicine Institutional Review Board (JHM IRB) (JHU); approved by Research Ethical Committee of Kanazawa Medical University (KMU); approved by Kyoto University Graduate School and Faculty of Medicine, Ethics Committee (Kyoto); approval by Research Ethics Committee, Osaka University (OSK); approved by Research Ethics Committee of the Faculty of Medicine of the University of Tokyo (Tokyo); and approved by Ethics Committee, University of Toyama (TYM).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos